Wird geladen...
Intrathecal effects of daclizumab treatment of multiple sclerosis
OBJECTIVES: We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that this response correlated with expansion of CD56(bright) NK cells...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Lippincott Williams & Wilkins
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3246406/ https://ncbi.nlm.nih.gov/pubmed/22076546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318239f7ef |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|